AUA 2026 preview: Practice-changing trials in benign urology

At the 2026 Annual Meeting of the American Urological Association in Washington, DC, the P2 plenary abstracts in benign urology are set to spotlight emerging technologies and late-breaking clinical data across stone disease, benign prostatic hyperplasia (BPH), and overactive bladder care. Presentations will feature pivotal trial updates tied to several recently cleared or approved devices, including the FDA-cleared Break Wave lithotripsy system for anesthesia-free stone treatment and the Urocross Expander System for lower urinary tract symptoms (LUTS) secondary to BPH.